iHeart Radio's "HealthTech Talk" Show to Feature MYOS Corporation's Ingredient Fortetropin(TM) in Exclusive Interview With Company Chairman - Seite 2
About HealthTech Talk Show
Health Tech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm - 4:00pm EST every
Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and
health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from
making people healthier. It's a fast moving, high-energy show... shift your thinking and join us as we deliver "tomorrow's ideas today" on iHeart Radio and Clear Channel's Health Tech Talk
Live. Visit iHeart Radio's HealthTech Talk Radio Show or visit www.HealthTechTalk.com.
About Dr. Robert Hariri
Dr. Robert Hariri is a surgeon, biomedical scientist and highly successful serial entrepreneur in two technology sectors: biomedicine and aerospace.
The Chairman, Founder, Chief Scientific Officer, and former Chief Executive Officer of Celgene Cellular Therapeutics, one of the world's largest human cellular therapeutics companies, Dr. Hariri
has pioneered the use of stem cells to treat a range of life threatening diseases and has made transformative contributions in the field of tissue engineering. In addition to his role at Celgene
Cellular Therapeutics, Dr. Hariri is also Vice-Chairman & Co-Founder of Human Longevity, Inc. (HLI).
His activities and experience includes academic neurosurgeon at Cornell, businessman, military surgeon and aviator and aerospace innovator. Dr. Hariri has over 90 issued and pending patents, has authored over 100 published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the placenta and as a member of the team which discovered the physiological activities of TNF (tumor necrosis factor).
Lesen Sie auch
Dr. Hariri was recipient of the Thomas Alva Edison Award in 2007 and 2011, The Fred J. Epstein Lifetime Achievement Award and has received numerous other honors for his many contributions to biomedicine and aviation. Dr. Hariri also serves on numerous Boards of Directors including Myos Corporation and Provista Diagnostics. Dr. Hariri is an Adjunct Associate Professor of Pathology at the Mount Sinai School of Medicine and a member of the Board of Visitors of the Columbia University School of Engineering & Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons, and is a member of the scientific advisory board for the Archon X PRIZE for Genomics, which is awarded by the X PRIZE Foundation. Dr. Hariri is also a Trustee of the Liberty Science Center and has been appointed Commissioner of Cancer Research by NJ Governor Christie. Dr. Hariri is also a member of the Board of Trustees of the J. Craig Venter Institute.